90 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
12 Apr 24
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise
8:05am
collaboration with our partner Genentech, and we continue to believe in the long-term potential of our iPSC-based allogeneic platform. Over the past
8-K
EX-10.3
ylg6e1s5n3jw
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
bmb5z5s
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
kbyatns19am4g
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
hngnf0vgtnektu2wn1
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
wlyp z60drytxdpc2t
30 May 23
Business combination disclosure
4:21pm
8-K
v0n4wxy vamxrsxid2ww
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
j2sjyv
22 May 23
Business combination disclosure
7:01am
8-K
vnfqflw 4t2j8p
22 May 23
Other Events
6:59am
8-K
EX-99.1
0vews86
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
05l1fouq oaqt4jxto2q
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
vezkx
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm